An Open-label Phase 1 Trial to Evaluate the Safety and Tolerability of a Modified Vaccinia Ankara (MVA) Priming Followed by Fowlpox Booster Vaccines Modified to Express Brachyury and T-cell Costimulatory Molecules (MVA-BN-Brachyury/FPV-Brachyury)
Latest Information Update: 05 Nov 2021
Price :
$35 *
At a glance
- Drugs MVA brachyury TRICOM vaccine (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Bavarian Nordic
- 25 Aug 2020 Status changed from active, no longer recruiting to completed.
- 29 Oct 2019 Planned End Date changed from 1 Nov 2024 to 1 Jun 2020.
- 29 Oct 2019 Planned primary completion date changed from 1 Mar 2020 to 1 Jun 2020.